Bure Equity AB (publ), corporate identity number 556454-8781, has acquired a total of 5,050,475 shares, which is equal to 6.23% of the total number of shares. The Annual General Meeting of Bure Equity AB (publ) (”Bure”) on 22 April 2013 resolved to authorise the company’s Board of Directors to decide on the acquisition of shares for the purpose of adapting the company’s capital structure to the company’s capital needs from time to time and thereby contribute to increased shareholder value. The company’s Board of Directors decided to exercise this authorisation. Bure has today acquired 1,000,000 shares on NASDAQ OMX Stockholm for a bid price of SEK 23.90 per share. Following this, Bure holds a total of 5,050,475 treasury shares of a total of 81,101,985 shares outstanding, which is equal to 6,23% of the total number of shares and votes in the company. Stockholm, 8 October 2013 Bure Equity AB (publ) Contacts at Bure: Henrik Blomquist, CEO Tel: +46 8-614 00 26 Max Jonson, CFO Tel: +46 8-614 00 29 The information contained herein is subject to the disclosure requirements of Bure Equity AB under the Swedish Securities Market Act. The information was publicly communicated on 8 October 2013, 4:00 p.m. CET Bure is a listed investment company with ownership interests in Nordic companies. The current portfolio consists of eight portfolio companies, of which five are listed.
Bure carries out share buyback Bure Equity AB (publ),
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care
Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...
Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series
Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...
Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects
Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...
Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy
Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...
Continue Reading
Investors Take Note: Legal Options for Shareholders Explored
Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...
Continue Reading